In cancer, NF-κB activation can lead to apoptosis resistance through the expression of inhibitors of apoptosis (IAPs), members of anti-apoptotic Bcl-2 family and also proteins that disrupt the death receptor apoptotic pathway (Wang et al., 1998; Catz and Johnson, 2001; Kreuz et al., 2001). This evidence concerns the gene BCL2 and cancer.